Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02172482 ·Status: COMPLETED

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

NCT02172495 ·Status: COMPLETED

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

NCT03265145 ·Status: COMPLETED ·Phase: PHASE4

Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

NCT02172521 ·Status: COMPLETED

Tiotropium / Respimat One-Year Study

NCT00168831 ·Status: COMPLETED ·Phase: PHASE3

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)

NCT00281567 ·Status: COMPLETED ·Phase: PHASE3

Spiriva® Assessment of FEV1 (SAFE)

NCT00277264 ·Status: COMPLETED ·Phase: PHASE3

A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00292448 ·Status: COMPLETED ·Phase: PHASE2

Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.

NCT02172547 ·Status: COMPLETED

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

NCT00240435 ·Status: COMPLETED ·Phase: PHASE3

Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00239499 ·Status: COMPLETED ·Phase: PHASE4

Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD

NCT00860938 ·Status: COMPLETED ·Phase: PHASE4

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT05986591 ·Status: COMPLETED ·Phase: PHASE3

Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD

NCT00274053 ·Status: COMPLETED ·Phase: PHASE3

Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema

NCT00570544 ·Status: COMPLETED

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

NCT00239447 ·Status: COMPLETED ·Phase: PHASE3

Bioequivalence Study of Tiotropium Bromide Inhalation Powder

NCT05161156 ·Status: COMPLETED ·Phase: PHASE3

Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example

NCT01036763 ·Status: COMPLETED

Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities

NCT00621582 ·Status: COMPLETED

Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea

NCT00540163 ·Status: COMPLETED

Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response

NCT06679465 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Tiotropium / Respimat One-Year Study

NCT00168844 ·Status: COMPLETED ·Phase: PHASE3

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773 ·Status: COMPLETED ·Phase: PHASE2

Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).

NCT00239408 ·Status: COMPLETED ·Phase: PHASE4